Independent, Scientific Studies
Modulation frequencies and cancer cells: what this study does not show
This page summarises a piece of published research that gets cited in bioresonance circles, and sets out plainly why it is not evidence for bioresonance.
The study
Zimmerman and colleagues, writing in the British Journal of Cancer in 2012, exposed liver cancer and breast cancer cell lines to amplitude-modulated electromagnetic fields at 27.12 MHz. The modulation frequencies used had been identified in patients by biofeedback. Growth of the cancer cells slowed at the tumour-specific frequencies, while randomly chosen control frequencies did nothing, and non-cancerous liver and breast cells were unaffected. The authors reported changes in two genes and disruption of the mitotic spindle, and concluded that the finding “may have broad implications in oncology”.
Source: Zimmerman JW et al., British Journal of Cancer, 2012.
What it does not show
It is worth being blunt about this, because the distinction gets lost.
- It is a different technology. The study used amplitude-modulated radiofrequency fields delivered through a spoon-shaped probe held in the mouth. That is not what a BICOM device does, and the two are not interchangeable.
- It was done in a dish, not in people. Cell lines under laboratory conditions are a long way from a patient, and results at that stage frequently do not carry across.
- It says nothing about bioresonance. Success reported for one frequency-based method is not evidence that another frequency-based method works the same way. No equivalent finding has been established for BICOM bioresonance.
We have kept this page because the research is real and practitioners ask about it. It is here as background reading, not as support for any claim about what bioresonance does.
Bioresonance is a complementary method. It is not a substitute for medical diagnosis or for oncological care, and nothing on this page should be read as an offer to treat cancer.
